Yourgene Health PLC DPYD kits recommended by NHS England
December 02 2020 - 01:00AM
RNS Non-Regulatory
TIDMYGEN
Yourgene Health PLC
02 December 2020
Yourgene Health plc
("Yourgene" or the "Group" or the "Company")
DPYD kits recommended by NHS England
Manchester, UK - 2 December 2020: Yourgene (AIM: YGEN), the
international molecular diagnostics group, welcomes the Clinical
Commissioning Urgent Policy Statement, published by NHS England,
titled: ' Pharmacogenomic testing for DPYD polymorphisms with
fluoropyrimidine therapies' recommending the routine availability
of DPYD testing prior to the start of treatment with
chemotherapeutic drug 5-Fluorouracil (5-FU), to identify the risk
of severe side effects.
This statement supports the use of Yourgene's oncology product,
Elucigene DPYD* test, which is already routinely being used in
Wales, as previously announced on 12 October 2020. There are seven
Genomic testing hubs in the NHS and currently three out of the
seven are using the Company's DPYD kits.
The full report can be found here: NHS England >> Clinical
Commissioning Urgent Policy Statement: Pharmacogenomic testing for
DPYD polymorphisms with fluoropyrimidine therapies
Lyn Rees, CEO of Yourgene, commented: "We are thrilled to see
NHS England issue this statement, recommending that DPYD testing is
routinely carried out prior to cancer treatment, highlighting the
importance of such test and improving care for cancer patients.
It's rewarding to see this has been published so soon after
becoming the sole supplier of DPYD in Wales and we look forward to
seeing this market grow further."
*Elucigene DPYD is a simple-to-use genotyping test that can
identify cancer patients with Dihydropyrimidine Dehydrogenase (DPD)
deficiency, which can cause severe and sometimes lethal side
effects in patients being treated with chemotherapeutic drug
5-Fluorouracil (5-FU), commonly used in the treatment of colon,
oesophageal, stomach, pancreatic, breast and cervical cancers. 5-FU
is metabolized by the DPD enzyme which is encoded by the DPYD
gene.
Yourgene Health plc Tel: +44 (0)161 669 8122
Lyn Rees, Chief Executive Officer investors@yourgene-health.com
Barry Hextall, Chief Financial Officer
Joanne Cross, Director of Marketing
N+1 Singer (Joint Corporate Broker) Tel: +44 (0)20 7496 3000
Aubrey Powell / Tom Salvesen / George
Tzimas
Stifel Nicolaus Europe Limited (Joint Tel: +44 (0)20 7710 7600
Corporate Broker)
Nicholas Moore / Matthew Blawat / Ben
Maddison
Walbrook PR Ltd (Media and Investor Tel: +44 (0)20 7933 8780 or yourgene@walbrookpr.com
Relations)
Paul McManus / Lianne Cawthorne Mob: 07980 541 893 / Mob: 07584
391 303
About Yourgene Health
Yourgene Health is an international molecular diagnostics group
which develops and commercialises genetic products and services.
The group works in partnership with global leaders in DNA
technology to advance diagnostic science.
Yourgene primarily develops, manufactures, and commercialises
simple and accurate molecular diagnostic solutions, for
reproductive health, precision medicine and now infectious
diseases. The Group's flagship products include non-invasive
prenatal tests (NIPT) for Down's Syndrome and other genetic
disorders, Cystic Fibrosis screening tests, invasive rapid
aneuploidy tests, and a recent extension into the oncology space
with DPYD genotyping.
The launch of Yourgene Genomic Services has enabled Yourgene to
offer a global laboratory service network equipped to be a full
life-cycle partner for clinical, research and pharmaceutical
organisations to support partners at the preclinical, clinical, and
post-market stages to develop, manufacture, obtain regulatory
approval and commercialise new products and services. In addition,
Yourgene Genomic Services offers an NIPT and high throughput COVID
testing service.
In August 2020, Yourgene acquired Coastal Genomics, Inc., a
sample preparation technology company based in Vancouver, Canada,
enabling the Company to extend its offering and IP portfolio in the
DNA sample preparation sector. The acquisition increased Yourgene's
geographical penetration into the US and Canada, supplementing
existing coverage in the UK, Europe, MEA and Asia.
Yourgene Health is headquartered in Manchester, UK with offices
in Taipei, Singapore, the US and Canada, and is listed on the
London Stock Exchange's AIM market under the ticker "YGEN". For
more information visit www.yourgene-health.com and follow us on
twitter @Yourgene_Health.
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRADFLFBBLLZFBZ
(END) Dow Jones Newswires
December 02, 2020 02:00 ET (07:00 GMT)
Yourgene Health (LSE:YGEN)
Historical Stock Chart
From Feb 2024 to Mar 2024
Yourgene Health (LSE:YGEN)
Historical Stock Chart
From Mar 2023 to Mar 2024